Metatinib Trometamol

麦他替尼氨丁三醇

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameMetatinib Trometamol
Drug Alias NameSIM-817378BMS-817378
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2Hepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursLiver NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingaporeAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Xiansheng Medicament Research Co LtdNanjing Simcere Dongyuan Pharmaceutical Co Ltd
Inactive CompaniesBristol Myers Squibb SrlcompanyJiangsu Simcere Pharmaceutical Co Ltd
Active IndicationsLiver NeoplasmsStomach Neoplasms
Inactive IndicationsSolid tumoursColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A